Core Viewpoint - The Meridian Hedged Equity Fund's third-quarter 2025 performance reflects a market more influenced by policy easing than weakening fundamentals, achieving a net return of 1.67% despite concerns over stagflation [1] Fund Performance - The fund's return of 1.67% in Q3 2025 is compared to the S&P 500 Index's return of 8.13% and the CBOE S&P 500 BuyWrite Index's return of 3.53% [1] Company Focus: Kenvue Inc. - Kenvue Inc. (NYSE:KVUE), a consumer health company with brands like Tylenol and Neutrogena, is highlighted as a key investment despite a one-month return of -0.06% and a 52-week loss of 21.06% [2][3] - Kenvue's stock closed at $17.02 on December 23, 2025, with a market capitalization of $32.609 billion [2] Investment Rationale for Kenvue Inc. - The fund sees potential for Kenvue to unlock value through reinvestment in underfunded brands, cost optimization, and margin improvement [3] - Recent market reactions to studies linking acetaminophen to autism risk during pregnancy are viewed as overblown, with minimal revenue impact expected from pregnant women, who represent less than 1% of Tylenol's global sales [3] Hedge Fund Interest - Kenvue Inc. was held by 73 hedge fund portfolios at the end of Q3 2025, an increase from 72 in the previous quarter, indicating growing interest [4] - Despite this interest, the fund suggests that certain AI stocks may offer greater upside potential and lower downside risk compared to Kenvue [4]

Core Insights - Class Action Attorney Juan Monteverde's firm has recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - Kenvue Inc. is under investigation regarding its sale to Kimberly-Clark Corporation, with shareholders set to receive $3.50 in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share [1] - FirstSun Capital Bancorp is merging with First Foundation Inc., with FirstSun shareholders expected to own 59.5% of the combined entity upon completion [2] - First Foundation shareholders will receive 0.16083 shares of FirstSun common stock for each share of First Foundation [3] - Gulf Island Fabrication, Inc. is being sold to IES Holdings, Inc., with shareholders to receive $12.00 in cash per share [4] Company Transactions - Kenvue Inc. shareholders will receive $3.50 in cash and 0.14625 shares of Kimberly-Clark for each share held [1] - FirstSun Capital Bancorp shareholders will own 59.5% of the merged company with First Foundation Inc. [2] - First Foundation Inc. shareholders will receive 0.16083 shares of FirstSun for each share held [3] - Gulf Island Fabrication, Inc. shareholders will receive $12.00 in cash per share in the transaction with IES Holdings, Inc. [4] Legal Context - Monteverde & Associates PC is a national class action securities firm with a successful track record in recovering funds for shareholders [5] - The firm operates from the Empire State Building and emphasizes the importance of legal representation for shareholders [5][6]

Core Insights - Kenvue Inc. was spun off from Johnson & Johnson in May 2023, aiming to establish itself as a stable entity in the market [1] Company Overview - The spin-off allows Kenvue to operate independently, focusing on its core business without the complexities associated with its parent company [1] Investment Perspective - The investment strategy emphasizes a fundamentals-first approach, highlighting the importance of uncovering mispriced assets that the market may overlook [1]

Group 1 - The article discusses the investment position of Parkev Tatevosian, CFA, who has no holdings in the stocks mentioned [1] - The Motley Fool has positions in and recommends Kenvue, indicating a positive outlook on the company [1] - There is a disclosure policy in place by The Motley Fool regarding potential compensation for promoting services [1]

分组1 - Johnson & Johnson (JNJ) spun off its consumer wellness division in 2023, creating a separate company named Kenvue (NYSE: KVUE) to unlock value for the overall enterprise [1] - The spin-off is expected to enhance the focus and operational efficiency of both JNJ and Kenvue, allowing each entity to pursue its strategic goals independently [1] 分组2 - Kenvue is positioned to capitalize on growth opportunities in the consumer wellness market, which may lead to increased shareholder value [1] - The separation of Kenvue from JNJ reflects a broader trend in the healthcare industry where companies are divesting non-core assets to streamline operations and enhance shareholder returns [1]

Group 1 - Johnson & Johnson (JNJ) spun off its consumer wellness division in 2023, creating a separate company named Kenvue (NYSE: KVUE) to unlock value for the overall enterprise [1] - The spin-off is expected to enhance the focus and operational efficiency of both JNJ and Kenvue, allowing each entity to pursue its strategic goals independently [1] Group 2 - Kenvue is positioned to capitalize on growth opportunities in the consumer wellness market, which may lead to increased shareholder value [1] - The separation of Kenvue from JNJ reflects a broader trend in the healthcare industry where companies are divesting non-core segments to streamline operations and enhance shareholder returns [1]

Core Thesis - Kenvue Inc. is undergoing a strategic review to optimize its brand portfolio and enhance operating performance, aiming to unlock shareholder value [2][3][4] Company Overview - Kenvue Inc. operates as a consumer health company across multiple regions including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [2] - As of November 28th, Kenvue's share price was $17.35, with a market capitalization of approximately $30 billion and an enterprise value of around $38 billion [3] Financial Metrics - Kenvue's trailing and forward P/E ratios are 23.13 and 15.77 respectively, with an EV/EBITDA multiple of roughly 11× [1][3] - The company offers a dividend yield of about 4%, providing a solid income component for investors [3] Strategic Initiatives - The strategic review may lead to the sale of underperforming Skin Health & Beauty brands, acquisitions in high-growth OTC health categories, and capital reallocation to higher-margin segments [4] - Analysts estimate that these initiatives could raise Kenvue's margins and overall valuation by 15–25% [4] Investment Case - The combination of a disciplined strategic review, potential divestitures, and a focus on higher-margin segments positions Kenvue to enhance profitability and shareholder returns over time [5] - Kenvue's current valuation and dividend yield, along with strategic initiatives, create an attractive investment case for those seeking operational upside and a clear path to value creation [5]

Core Insights - Class Action Attorney Juan Monteverde's firm has successfully recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] Group 1: Repare Therapeutics Inc. - Repare Therapeutics Inc. is being investigated regarding its sale to XenoTherapeutics, Inc. [1] - Upon closing, each Repare shareholder is expected to receive a cash payment of $1.82 per share, along with a non-transferable contingent value right for additional cash payments under certain conditions [1] Group 2: CNB Bank Shares, Inc. - CNB Bank Shares, Inc. is involved in a sale to HBT Financial, Inc. [2] - CNB shareholders will receive either 1.0434 shares of HBT common stock, $27.73 in cash per share, or a combination of both upon completion of the transaction [2] Group 3: Kimberly-Clark Corporation - Kimberly-Clark Corporation is merging with Kenvue Inc. [3] - Post-merger, Kimberly-Clark shareholders are expected to own approximately 54% of the combined company [3] Group 4: Kenvue Inc. - Kenvue Inc. is being sold to Kimberly-Clark Corporation [4] - Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share [4]

Core Insights - Kenvue Inc. (NYSE:KVUE) is currently under scrutiny due to litigation concerns, but the overall sentiment from analysts suggests that long-term shareholders should not be overly worried [1][2] - The company operates in the consumer health products sector, offering well-known brands such as Tylenol, Motrin, Calpol, Neutrogena, and Band-Aid [2] Company Overview - Kenvue Inc. provides a range of consumer health products, including pain relief, allergy care, digestive support, wellness, and personal care [2] - The stock is currently at a 4.5% yield, and the company has new leadership in place [2] Analyst Sentiment - Jim Cramer believes that while there will be lawsuits, the situation is manageable and not as dire as perceived [1][2] - Cramer does not expect significant upside for Kenvue's stock in the near term, indicating a cautious outlook [2]

Core Insights - Cullen Capital Management's "SCCM Value Equity Strategy" reported a gross return of 6.9% for Q3 2025, outperforming the Russell 1000 Value's 5.3% and underperforming the S&P 500's 8.1% during the same period [1] - Year-to-date, the strategy achieved a gross return of 13.0%, compared to Russell 1000 Value's +11.7% and S&P 500's +14.8% [1] Company Analysis: Kenvue Inc. (NYSE:KVUE) - Kenvue Inc. experienced a one-month return of 6.43% but has lost 33.33% of its value over the past 52 weeks, with a market capitalization of $30.82 billion as of November 19, 2025 [2] - The company was sold from the SCCM Value Equity Strategy during Q3 2025 due to challenges such as pressures on US consumer spending, delayed seasonal demand, and competition from challenger brands [3] - Kenvue's stock is currently valued at 19x 2025 EPS, which is considered less compelling compared to its initial portfolio addition in 2023 [3] Market Position - Kenvue Inc. is not among the 30 most popular stocks among hedge funds, although it saw an increase in hedge fund holdings from 52 to 72 in the last quarter [4] - Despite its potential, Kenvue is viewed as less attractive compared to certain AI stocks that are believed to offer greater upside potential and lower downside risk [4]